Approval · Notice of Compliance 2123 · 2001
CEFTIN: Notice of Compliance 2123
Issued June 22, 2001
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 2123
- Date
- June 22, 2001
- Company
- Glaxosmithkline IncMississauga, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- Admin
- Reason
- Change in manufacturer name
- Therapeutic class
- Antibiotic
Products in this notice
Medicinal ingredients
- CEFUROXIME AXETIL 250 MG per TAB
- CEFUROXIME AXETIL 250 MG per PCK
- CEFUROXIME AXETIL 125 MG per 5ML
- CEFUROXIME AXETIL 500 MG per TAB